Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NW-Si-2301
- Development stage
- Preclinical
- Lead developer
- Novelwise Pharmaceutical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
NW-Si-2301 is an investigational small interfering RNA (siRNA) therapeutic being developed by Novelwise Pharmaceutical for the treatment of glioblastoma. Utilizing RNA interference (RNAi) technology, the candidate is designed to achieve highly specific and durable gene silencing of a disease-associated target gene involved in glioblastoma progression. NW-Si-2301 is currently in early-stage preclinical development as part of Novelwise's expanding pipeline of RNAi-based oncology therapeutics.
Beyond the preview
Go deeper on NW-Si-2301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NW-Si-2301.